Omnicell Inc

OMCL remains in a sustained downtrend, forming sequential lower highs and lower lows under a declining EMA/SMA stack. Medium-term bias is bearish, and short-term timing is favorable as price is rejecting rallies into the 9-day and 20-day EMA resistance zone. Execution favors selling now into that EMA region. Key risks include a potential oversold bounce and any sustained break above the EMA resistance that would invalidate the bearish structure.

• ↑Q1 2026 revenue $310M (+15% YoY); non-GAAP EBITDA $45M
• ↑ARR projected at $680–700M by end-2026
• ↓Non-GAAP gross margins fell to 50%, profitability score negative